- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 7
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 7, 2017.
Transcript
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 7.
Number 5: Some health plans are telling consumers that they must purchase brand name drugs, even when cheaper generics are available, leading to higher out-of-pocket costs for patients.
Number 4: The FDA’s Office of Surveillance has released findings from an inspection of Biocon’s troubled manufacturing facility in Bangalore. The investigators found 10 problems, including issues with labeling and sterility.
Number 3: A recent study comparing biosimilar GP2013 to both EU- and US-approved rituximab shows 3-way PK and PD equivalence in patients with rheumatoid arthritis.
Number 2: FDA Commissioner, Dr Scott Gottlieb, has formed a new working group within the agency. The group will focus on increasing generic competition.
And Number 1: Pharmacist Kyle Skiermont, COO of Fairview Pharmacy Services, discusses his experience with payers and healthcare providers as they prepare for the impact of biosimilar drugs and non-medical switching.
Finally, last week, our newsletter asked you to share your thoughts on whether interchangeability will be important to the uptake of biosimilars. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read these articles and more, visit centerforbiosimilars.com.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
